Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „formulation“
Suchtreffer
Begriffe & Kennungen
Aerius · 4.8 · In clinical trials in a paediatric population, the desloratadine syrup formulation was administered to a total
Eintrag öffnenAmbirix · 4.8 · * refers to adverse reactions observed in clinical trials performed with the paediatric formulation
Eintrag öffnenArzneimittelherstellung
Eintrag öffnenAzomyr · 4.8 · In clinical trials in a paediatric population, the desloratadine syrup formulation was administered to a total
Eintrag öffnenColobreathe · 4.5 · Caution should be taken with concomitant use with other formulations of colistimethate sodium as there is litt
Eintrag öffnenDarzalex · 4.5 · Clinical pharmacokinetic assessments with daratumumab intravenous or subcutaneous formulations and lenalidomid
Eintrag öffnenDarzalex · 4.8 · In patients with AL amyloidosis receiving DARZALEX subcutaneous formulation combination therapy, the following
Eintrag öffnenDarzalex · 4.8 · In patients with multiple myeloma receiving DARZALEX subcutaneous formulation combination therapy, the followi
Eintrag öffnenDarzalex · 4.8 · Injection site reactions (ISRs) In clinical studies (N=1573) with DARZALEX subcutaneous formulation, the incid
Eintrag öffnenDarzalex · 4.8 · Table 9 summarises the adverse reactions that occurred in patients receiving DARZALEX subcutaneous formulation
Eintrag öffnenDarzalex · 4.8 · The data reflects exposure to DARZALEX subcutaneous formulation (1800 mg) in 1187 patients with multiple myelo
Eintrag öffnenDarzalex · 4.8 · The safety profile of the DARZALEX subcutaneous formulation was similar to that of intravenous formulation wit
Eintrag öffnenDepotpräparate
Eintrag öffnenFormeldiät
Eintrag öffnenForschungsdesign
Eintrag öffnenGanfort · 4.8 · Table 1: List of adverse reactions with all GANFORT formulations (multi-dose and single-dose)
Eintrag öffnenGanfort · 4.8 · Table 1: List of adverse reactions with all GANFORT formulations (multi-dose and single-dose)
Eintrag öffnenHerceptin · 4.8 · 41 The safety profile of Herceptin subcutaneous formulation (evaluated in 298 and 297 patients treated with th
Eintrag öffnenHerceptin · 4.8 · Description of selected adverse reactions with the subcutaneous formulation
Eintrag öffnenHerceptin · 4.8 · In the pivotal trial, the rate of all grade ARRs was 37.2 % with the Herceptin intravenous formulation and 47.
Eintrag öffnen